Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017254661> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3017254661 abstract "<h3>Background and importance</h3> Osimertinib improves progression free survival (PFS) in previously untreated patients with EGFR mutated non-small cell lung cancer (NSCLC). However, its profitability has not been established in a third level hospital. <h3>Aim and objectives</h3> The aim of the study was to evaluate the cost effectiveness of osimertinib in patients with mutated EFGR NSCLC compared with other tyrosine kinase inhibitors (TKIs). <h3>Material and methods</h3> This was a cost effectiveness study of osimertinib in patients with EFGR mutated NSCLC in a third level hospital over a period of 1 year of treatment (1 January 2018 to 12 January 2019). The protocol of the hospital was reviewed to include all therapeutic alternatives: afatinib, gefitinib and erlotinib. The main variable of the study was the incremental cost effectiveness ratio (ICER) of osimertinib compared with other TKIs. Secondary variables included: cost of treatment per month (€), efficacy (life months gained), total cost of treatment (€) and incremental cost of osimertinib compared with other TKIs. <h3>Results</h3> The incremental cost effectiveness ratios of osimertinib compared with each TKI were: Osimertinib versus erlotinib: €6896/month of PFS. Osimertinib versus gefitinib: €7931/month of PFS. Osimertinib versus afatinib: €7067/month of PFS. <h3>Conclusion and relevance</h3> At the current commercialised price, firstline osimertinib therapy in patients with EGFR mutant NSCLC would mean an incremental cost of €7455±€439 per month of PFS gained compared with other TKIs. If we consider a year of treatment, the incremental cost of osimertinib would be an additional €74547±4388. The reduction in cost of osimertinib would significantly improve its cost effectiveness profile. The main limitation of this study was that the cost of the complete treatment was calculated using the drug’s PVL. <h3>References and/or acknowledgements</h3> No conflict of interest." @default.
- W3017254661 created "2020-04-24" @default.
- W3017254661 creator A5006840452 @default.
- W3017254661 creator A5030552012 @default.
- W3017254661 creator A5033055030 @default.
- W3017254661 creator A5057292633 @default.
- W3017254661 creator A5062012854 @default.
- W3017254661 creator A5073754705 @default.
- W3017254661 creator A5076265049 @default.
- W3017254661 creator A5077340279 @default.
- W3017254661 creator A5084973058 @default.
- W3017254661 date "2020-03-01" @default.
- W3017254661 modified "2023-09-26" @default.
- W3017254661 title "2SPD-005 Economic analysis of osimertinib in previously untreated EGFR mutant advanced non-small cell lung cancer" @default.
- W3017254661 doi "https://doi.org/10.1136/ejhpharm-2020-eahpconf.24" @default.
- W3017254661 hasPublicationYear "2020" @default.
- W3017254661 type Work @default.
- W3017254661 sameAs 3017254661 @default.
- W3017254661 citedByCount "0" @default.
- W3017254661 crossrefType "proceedings-article" @default.
- W3017254661 hasAuthorship W3017254661A5006840452 @default.
- W3017254661 hasAuthorship W3017254661A5030552012 @default.
- W3017254661 hasAuthorship W3017254661A5033055030 @default.
- W3017254661 hasAuthorship W3017254661A5057292633 @default.
- W3017254661 hasAuthorship W3017254661A5062012854 @default.
- W3017254661 hasAuthorship W3017254661A5073754705 @default.
- W3017254661 hasAuthorship W3017254661A5076265049 @default.
- W3017254661 hasAuthorship W3017254661A5077340279 @default.
- W3017254661 hasAuthorship W3017254661A5084973058 @default.
- W3017254661 hasBestOaLocation W30172546611 @default.
- W3017254661 hasConcept C112930515 @default.
- W3017254661 hasConcept C121608353 @default.
- W3017254661 hasConcept C126322002 @default.
- W3017254661 hasConcept C143998085 @default.
- W3017254661 hasConcept C2776256026 @default.
- W3017254661 hasConcept C2776694085 @default.
- W3017254661 hasConcept C2777626846 @default.
- W3017254661 hasConcept C2778087573 @default.
- W3017254661 hasConcept C2779438470 @default.
- W3017254661 hasConcept C2780580887 @default.
- W3017254661 hasConcept C2780586478 @default.
- W3017254661 hasConcept C2780739268 @default.
- W3017254661 hasConcept C3019080777 @default.
- W3017254661 hasConcept C71924100 @default.
- W3017254661 hasConceptScore W3017254661C112930515 @default.
- W3017254661 hasConceptScore W3017254661C121608353 @default.
- W3017254661 hasConceptScore W3017254661C126322002 @default.
- W3017254661 hasConceptScore W3017254661C143998085 @default.
- W3017254661 hasConceptScore W3017254661C2776256026 @default.
- W3017254661 hasConceptScore W3017254661C2776694085 @default.
- W3017254661 hasConceptScore W3017254661C2777626846 @default.
- W3017254661 hasConceptScore W3017254661C2778087573 @default.
- W3017254661 hasConceptScore W3017254661C2779438470 @default.
- W3017254661 hasConceptScore W3017254661C2780580887 @default.
- W3017254661 hasConceptScore W3017254661C2780586478 @default.
- W3017254661 hasConceptScore W3017254661C2780739268 @default.
- W3017254661 hasConceptScore W3017254661C3019080777 @default.
- W3017254661 hasConceptScore W3017254661C71924100 @default.
- W3017254661 hasLocation W30172546611 @default.
- W3017254661 hasOpenAccess W3017254661 @default.
- W3017254661 hasPrimaryLocation W30172546611 @default.
- W3017254661 hasRelatedWork W2734557114 @default.
- W3017254661 hasRelatedWork W2805264144 @default.
- W3017254661 hasRelatedWork W2960110985 @default.
- W3017254661 hasRelatedWork W3017254661 @default.
- W3017254661 hasRelatedWork W3030098781 @default.
- W3017254661 hasRelatedWork W3169975926 @default.
- W3017254661 hasRelatedWork W4210252067 @default.
- W3017254661 hasRelatedWork W4210359084 @default.
- W3017254661 hasRelatedWork W4285031963 @default.
- W3017254661 hasRelatedWork W4307234767 @default.
- W3017254661 isParatext "false" @default.
- W3017254661 isRetracted "false" @default.
- W3017254661 magId "3017254661" @default.
- W3017254661 workType "article" @default.